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A B S T R A C T
Purpose
Despite increasing awareness of accrual challenges, it is unknown if accrual of older patients to
breast cancer treatment trials is improving.
Methods
We examined accrual of older patients to Alliance for Clinical Trials in Oncology systemic therapy
breast cancer trials during 1985-2012 and compared disease characteristics and reasons for therapy
cessation for older (age$ 65 years and$ 70 years) versus younger (age, 65 years and, 70 years)
participants. To examine accrual trends, we modeled age as a function of time, using logistic
regression.
Results
Overall, 17% of study participants were $ 65 years of age. Approximately 15%, 24%, and 24% of
participants in adjuvant, neoadjuvant, and metastatic trials were age$ 65 years, and 7%, 15%, and
13%were age$ 70 years, respectively. The odds of a patient age$ 65 years enrolling significantly
increased over time for adjuvant trials (odds ratio [OR] per year, 1.04; 95% CI, 1.04 to 1.05) but
decreased significantly for neoadjuvant andmetastatic trials (OR, 0.62; 95%CI, 0.58 to 0.67 and OR,
0.98, 95% CI, 0.97 to 1.00). Similar trends were seen for those age $ 70 years but these were
statistically significant for adjuvant and neoadjuvant trials only (OR, 1.05, 95% CI, 1.04 to 1.07; and
OR, 0.57, 95% CI, 0.52 to 0.62). In general, those age $ 65 years (v those , 65 years) in adjuvant
studies had a higher mean number of lymph nodes involved and more hormone receptor-negative
tumors, although tumor sizes were similar. Early protocol treatment cessation was also more
frequent in those age $ 65 years (50%) versus , 65 years (35.9%) across trials.
Conclusion
Older patients with breast cancer remain largely underrepresented in cooperative group therapeutic
trials. We observed some improvement in accrual to adjuvant trials but worsening of accrual for
neoadjuvant/metastatic trials. Novel strategies to increase accrual of older patients are critical to
meaningfully change the evidence base for this growing patient population.
J Clin Oncol 35:421-431. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer is a disease of aging and nearly
72,000 breast cancers occur annually in US women
$ 70 years of age.1,2 Althoughmost breast cancers in
older women are lower-risk tumors and most older
patients with breast cancer die of other causes,3-5
approximately 19,000 breast cancer deaths occur
yearly in USwomen$ 70 years of age, accounting
for 47% of breast cancer deaths.6
Although most cancers occur in older patients,
accrual of older patients to cancer clinical trials has
been a persistent challenge. Consequently, the
availability of prospective data for older patients
with breast cancer is limited. Although some ev-
idence suggests that older patients are just as likely
to enroll in clinical trials as younger patients if one
is offered,7 multiple barriers to accrual have been
identified, including comorbidity, physician/patient
preferences, socioeconomic factors, insurance,
concerns about loss of continuity with primary on-
cologists, lack of knowledge about clinical trials, and
age itself.7-18 In addition, others have cited time and
travel considerations and trial phase as barriers for
all patients.16,19 Thus far, specific efforts to improve
enrollment of older patients with cancer to clinical
trials within the cooperative group setting have
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Table 1. Alliance for Clinical Trials in Oncology
Trial Agents Administered Key Eligibility*
Total Patients
in Study, No.
Age $ 65
Years,
No. (% total
accrual)
Age $ 70
years,
No. (% total
accrual) Dates of Accrual
All trials combined — — 19,507 3,308 (17) 1,672 (9) 1985-2012
Adjuvant trials (overall) 15,297 2,277 (15) 1099 (7) 1985-2010
CALGB 4010132,33 A+C v T (4 v 6 cycles) • 0-3 nodes involved 3,871 468 (12) 177 (5) 6/2002-7/2010
• No locally advanced
disease
• ECOG PS not specified
CALGB 49907†24 A+C/C+M+F v capecitabine • Age $ 65 years 633 633 (100) 415 (66) 6/2002-12/2006
• Tumor . 1 cm
• Life expectancy . 5 years
• ECOG PS 0-2
NCCTG N983134 A+C+T v A+C+T+H • HER2 positive 3,505 301 (9) 126 (4) 5/2000-4/2005
• Node positive or higher risk
node negative
• ECOG PS not specified
CALGB 974135 A+C+T q2w v A+C+T q3w v
sequential A+T+C q2w
• T0-T3, N1/2, M0 disease 2,005 162 (8) 54 (3) 10/1997-3/1999
• ECOG PS not specified
CALGB 934436 A+C with 3 different doses
of A (60, 75, 90 mg/m2) 3
4 cycles 6 T
• Node positive 3,170 182 (6) 55 (2) 5/1994-4/1997
• ECOG PS not specified
NCCTG 89-30-52‡37 Tamoxifen 6 fluoxymesterone • Postmenopausal 541 381 (70) 225 (42) 1/1991-4/1995
• Estrogen-receptor positive
• T1 or T2
• If node negative, any age
allowed
• If node positive, required to
be age $ 65 years
• ECOG PS not specified
CALGB 854138 C+A+F dosing (3 dose levels
examined)
• Stage II (T1N0M0 or
T2N1M0)
1,572 150 (10) 47 (3) 1/1985-3/1991
• ECOG PS 0-1
Neoadjuvant trials (overall) 1,663 407 (24) 252 (15) 2006-2012
CALGB 4060339 A+C+T 6 carboplatin 6
bevacizumab
• Triple negative 454 40 (9) 10 (2) 7/2009-8/2012
• Clinical stage II-III
• ECOG PS not specified
CALGB 4060140 T+H v T+H+L v T+L • HER2 positive 305 25 (8) 10 (3) 2/2009-2/2012
• Clinical stage II-III
• ECOG PS not specified
ACOSOG Z104141 Preoperative F+E+C→T+H v T
+H→F+E+C+H
• HER2 positive 282 18 (6) 8 (3) 9/2007-12/2011
• T2 or node positive
• ECOG PS 0-1
ACOSOG Z1031‡42 Preoperative exemestane v
letrozole v anastrozole
• Postmenopausal 622 324 (52) 224 (36) 01/2006-01/2009
• HR positive
• HER2 negative
• Clinical T2-T4c, N0-3, M0
• ECOG PS 0-2
Metastatic trials (overall) 2,547 624 (24) 321 (13) 1994-2011
CALGB 4050243 Weekly paclitaxel v
nab-paclitaxel v ixabepilone
• HER2 negative 799 166 (21) 81 (10) 11/2008-11/2011
• Stage IIIC or IV
• First-line chemotherapy
• ECOG PS 0-1
CALGB 4050344 Letrozole/tamoxifen 6
bevacizumab
• HR positive 394 98 (25) 53 (13) 9/2008-11/2011
• Metastatic
• First-line patients only
• ECOG PS 0-1
CALGB 40302‡45 Fulvestrant 6 lapatinib • HR positive 295 84 (28) 47 (16) 12/2006-07/2010
• Postmenopausal
• Noncurative stage III or
stage IV
• 1-2 prior endocrine
therapies allowed
• ECOG PS 0-2
CALGB 934246 Paclitaxel dosing • # 1 prior line of
chemotherapy
474 149 (31) 87 (18) 9/1998-11/2003
• Metastatic disease
• ECOS PS not specified
(continued on following page)
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included educational interventions,20 focused committees, policy
statements,21-23 and the development of a limited number of trials
dedicated to older patients.24-26 Additional attempts to improve
accrual across all ages have examined strategies to improve the
consent process and the methods for opting in/out of enrollment.27-29
Because of keen awareness of accrual challenges for older
patients, designing clinical trials specific to older patients with
cancer has been a priority.22,23,30 We have seen some successes with
Cancer and Leukemia Group B (CALGB) trials 9343 and 49907,24-26
though there is concern that we continue to struggle with enrollment
of older patients.22 The Alliance for Clinical Trials in Oncology
(“Alliance”; formed by the merger of legacy groups CALGB,
American College of Surgeons Oncology Group [ACOSOG], and
North Central Cancer Treatment Group [NCCTG]) has a national
therapeutic protocol program in breast cancer31 and has completed
many practice-changing, large-scale systemic trials to date. However, it
is not known if accrual of older patients to these trials has improved. In
this retrospective analysis (A151527), we examined whether enroll-
ment of older patients with breast cancer to Alliance systemic therapy
clinical trials has improved over time. We also examined disease
characteristics and the reasons for study treatment cessation for those
age $ 65 years and $ 70 years versus younger patients.
METHODS
Data Source
We reviewed the Alliance portfolio of accrued systemic therapy trials
in neoadjuvant, adjuvant, and metastatic breast cancer therapeutic settings
during 1985-2012. Because of specific concerns about the lack of en-
rollment of older patients in systemic treatment trials in particular, we
focused our analysis on therapeutic systemic trials only and did not include
local or supportive therapy protocols. Table 1 lists the trials included.
Variables of Interest
Our primary end point was the proportion of older patients enrolled
in studies over time, using the date of protocol registration for each patient.
We determined whether the probability of an older patient enrolling in
a study changed significantly over time. We examined both the overall time
trend for all studies and the time trends specific to trial type (separately) for
adjuvant, neoadjuvant, and metastatic trials. Our secondary goal was to
better understand whether disease characteristics for trial participants
differed by age by examining tumor size, number of nodes involved,
hormone receptor status, and human epidermal growth factor 2 (HER2)
receptor status (when available) for older versus younger women in each
adjuvant study. We limited comparisons of disease characteristics to
adjuvant trials because neoadjuvant and metastatic trials primarily en-
rolled patients with homogeneous staging and tumor subtypes. When
available, we also examined baseline Eastern Cooperative Oncology
Group (ECOG) performance status (PS)48 and reasons for protocol therapy
cessation by age.
Statistical Analysis
To determine whether the proportion of older patients enrolling in
trials changed over time, we modeled age as a function of time, using
logistic regression, both for age $ 65 years (v , 65 years) and age $ 70
years (v , 70 years). This was done separately for adjuvant, neoadjuvant,
and metastatic trials, using data pooled across all available studies for each
trial setting. Of note, CALGB 49907, NCCTG 89-30-52, and ACOSOG
Z1031 primarily targeted postmenopausal and/or older women, enrolling
patients age $ 65 years at rates of 100%, 70%, and 52%, respectively.
Therefore, in a sensitivity analysis, we repeated analyses with these trials
excluded.
To assess the degree to which disease characteristics differed with age
for each adjuvant study, we compared subtype (estrogen receptor [ER],
progesterone receptor [PR], and HER2 receptor status), tumor size, and
the number of nodes involved for patients (when data were available) in
each adjuvant study, using x2 tests for comparisons of receptor status and
tumor size and paired t tests for comparison of nodes. We also examined
differences in ECOG PS and reasons for protocol therapy cessation (overall
and for each trial type separately) by age, using x2 tests.
Because this study used preexisting data, we received exemption from
the Dana-Farber Cancer Institute Office for Human Research Studies for
these analyses. Data collection and statistical analyses were conducted by
the Alliance Statistics and Data Center.
RESULTS
Accrual Over Time
We included 16 Alliance protocols, which enrolled 19,507
patients. The proportion of patients age$ 65 years and$ 70 years
enrolled in each study, agents administered, key eligibility, and
Table 1. Alliance for Clinical Trials in Oncology (continued)
Trial Agents Administered Key Eligibility*
Total Patients
in Study, No.
Age $ 65
Years,
No. (% total
accrual)
Age $ 70
years,
No. (% total
accrual) Dates of Accrual
CALGB 984047 Paclitaxel schedules (weekly v
q3w + trastuzumab if HER2
positive
• HER2 positive or negative 585 127 (22) 53 (9) 2/1994-7/1997
• # 1 prior line of
chemotherapy for
metastatic disease or
locally advanced
• ECOS PS not specified
NOTE. Adjuvant, neoadjuvant, and metastatic studies included (most recent to oldest). Dashes indicate not applicable.
Abbreviations: A, doxorubicin; ACOSOG, American College of Surgeons Oncology Group; CALGB, Cancer and Leukemia Group B; C, cyclophosphamide; E, epirubicin;
ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; F, 5-fluorouracil; H, trastuzumab; HER2, human epidermal growth factor
receptor 2; HR, hormone receptor; L, lapatinib; M,methotrexate; NCCTG, North Central Cancer Treatment Group; q2w, every 2weeks; q3w, every 3weeks; T, paclitaxel.
*Only key and relevant eligibility criteria are listed; this is not complete. “ECOGPS not specified” indicates this was not described in the publication, but it is possible this
was on the list of exclusions/inclusions in protocol documents.
†Age $ 65 years was an eligibility requirement.
‡Postmenopausal status was an eligibility requirement.
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dates of accrual are listed in Table 1. No trial had an upper limit for
age as part of eligibility requirements. Overall, 3,308 (17%) of the
19,507 trial participants registered during 1985-2012 were age$ 65
years and 1,672 (9%) were age $ 70 years.
Among the 15,297 women who enrolled in adjuvant trials,
15% were age $ 65 years and 7% were $ 70 years. For the 1,663
women enrolled in neoadjuvant studies, 24% were age $ 65 years
and 15% of participants were$ 70 years. Of the 2,547 participants
in metastatic protocols, 24% were age $ 65 years and 13% were
$ 70 years. Figure 1 displays the proportion of older women
enrolled by trial. Distinct peaks in enrollment for older patients are
visible for CALGB 49907 (adjuvant chemotherapy for patients
age $ 65 years), NCCTG 89-30-52, and ACOSOG Z1031 (hor-
monal therapy-based trials for postmenopausal women).
The absolute numbers of patients age$ 65 years and age$ 70
years increased somewhat over the study period (Appendix Fig A1,
online only), although this was not consistent over time. For ex-
ample, the years with the lowest absolute numbers of enrolled
patients age$ 65 years were 1991 (n = 7), 2012 (n = 15), and 1985
(n = 31), whereas the highest numbers of enrolled older patients
occurred during 2000 (n = 467), 2010 (n = 282), and 2009 (n = 246).
Figure 2 displays the trends in overall accrual over time by age
(Fig 2A), trends in accrual by trial type for age$ 65 years (Fig 2B)
and $ 70 years (Fig 2C), and trends by ages $ 65 years and $ 70
years after excluding CALGB 49907/NCCTG 89-30-52/ACOSOG
Z1031 (Fig 2D). To further illustrate potential trends in each of
these plots, we included locally weighted scatterplot smoothing
lines (a type of nonparametric regression).
Results from our logistic regression model indicate that the
odds of a patient age $ 65 years enrolling slightly increased with
each year in adjuvant trials, with an odds ratio (OR) for enrollment
of 1.04 per year (95%CI, 1.04 to 1.05; P, .001). Thus, over 5 years,
this translates into a 20% increase in the odds of enrolling patients
age $ 65 years. In contrast, the odds of a patient age $ 65 years
enrolling decreased significantly by year in neoadjuvant and
metastatic trials (OR, 0.62; 95% CI, 0.58 to 0.67; P, .001; and OR,
0.98, 95% CI, 0.97 to 1.00, P = .03, respectively). Similar trends
were seen for patients age $ 70 years, but these were statistically
significant for adjuvant and neoadjuvant trials only (OR, 1.05; 95%
CI, 1.04 to 1.07; and OR, 0.57; 95% CI, 0.52 to 0.62, respectively).
After exclusion of patients enrolled in CALGB 49907/NCCTG
89-30-52/ACOSOG Z1031, results were unchanged for adjuvant
and metastatic trials, but no significant time trend was found for
neoadjuvant trials.
Disease Characteristics and ECOG PS by Age
Disease characteristics by age for adjuvant trials CALGB
40101, 49907, 9344, 9741, 9344, 8541, and N9831 are listed in
Table 2 (detailed characteristics for NCCTG 89-30-52 were not
available). In general, across adjuvant trials, the proportion of
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Fig 1. Proportions of patients age$ 65 years and$ 70 years enrolled in each clinical trial. ACOSOG, American College of Surgeons Oncology Group; CALGB, Cancer and
Leukemia Group B; NCCTG, North Central Cancer Treatment Group.
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women with ER-negative and PR-negative tumors was significantly
higher for older versus younger women. Comparisons by HER2
status were limited because these data were not routinely collected
in older studies and because all patients in N9831 had HER2-
positive disease. For CALGB studies 40101, 8541, 9344, and 9741,
the mean number of nodes in women age $ 65 years was higher
than in younger patients. Mean tumor sizes were similar by age for
all adjuvant studies (P . .05 for all five protocols), although when
categorized as , 2 cm or $ 2 cm, CALGB 40101 had a higher
proportion of patients age $ 65 years with tumors $ 2 cm
compared with those age , 65 years (49% v 44%, respectively;
P = .019). Results for age $ 70 years were similar to those with
a cutoff age of 65 years (data not shown). Patients age $ 65 years
and$ 70 years had significantly higher proportions of participants
with ECOG PS 1 (v 0) in CALGB studies 40101, 40302, and 40603
compared with younger women. ECOG PS was similar by age in
CALGB 40502 and 9840 (Table 3).
Reasons for Protocol Treatment Cessation
Table 4 lists the reasons for stopping protocol treatment
(based on trials with this information available). Overall, reasons
for going off treatment differed significantly for women age $ 65
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Fig 2. Unadjusted proportions of patients age$ 65 years and$ 70 years enrolled in all trials (A), by trial type for age$ 65 years and$ 70 years (B, C), and after exclusion
of Cancer and Leukemia Group B (CALGB) 49907, North Central Cancer Treatment Group (NCCTG) 89-30-52, and American College of Surgeons Oncology Group
(ACOSOG) Z1031 (D).
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Table 2. Disease Characteristics by Adjuvant Trial for Older Versus Younger Women*
Variables by Protocol Total* Age , 65 Years Age $ 65 Years Age $ 70 Years†
P‡ (age , 65
years v $ 65 years)
CALGB 4010132,33 3,864 3,396 468 177
ER .024
Positive 2,564 (66) 2,275 (67) 289 (62) 103 (58)
Negative 1,298 (34) 1,119 (33) 179 (38) 74 (42)
Missing/unknown 2 (0) 2 (0) 0 (0) 0 (0)
PR .011
Positive 2,175 (56) 1,937 (57) 238 (51) 87 (49)
Negative 1,681 (44) 1,452 (43) 229 (49) 90 (51)
Missing/unknown 8 (0) 7 (0) 1 (0) 0 (0)
HER2 .140
Positive 719 (19) 620 (18) 99 (21) 32 (18)
Negative 3,017 (78) 2,662 (78) 355 (76) 138 (78)
Missing/unknown 128 (3) 114 (3) 14 (3) 7 (4)
Mean no. of nodes involved (range) 0.2 (0-17) 0.2 (0-17) 0.4 (0-8) 0.6 (0-8) , .001
Tumor size, cm .019
, 2 2,152 (56) 1,915 (56) 237 (51) 80 (68)
$ 2 1,712 (44) 1,481 (44) 231 (49) 97 (32)
CALGB 49907 633 — 633 415
ER N/A N/A
Positive 417 (66) 417 (66) 260 (63)
Negative 214 (34) 214 (34) 155 (24)
Missing/unknown 2 (0) 2 (0) 0 (0)
PR N/A N/A
Positive 333 (53) 333 (53) 199 (48)
Negative 296 (47) 296 (47) 214 (52)
Missing/unknown 4 (1) 4 (1) 2 (0)
HER2 N/A N/A
Positive 76 (12) 76 (12) 48 (12)
Negative 529 (84) 529 (84) 349 (84)
Missing/unknown 28 (4) 28 (4) 18 (4)
Mean no. of nodes involved (range) 2.0 (0-20) N/A 2.0 (0-20) 2.3 (0-20) N/A
Tumor size, cm N/A N/A
, 2 229 (36) 229 (36) 135 (33)
$ 2 401 (64) 401 (64) 279 (67)
NCCTG N983134 3,505 3,204 301 126
ER .014
Positive 1,841 (53) 1,707 (53) 134 (45) 55 (44)
Negative 1,663 (47) 1,496 (47) 167 (55) 71 (56)
Missing/unknown 0 (0) 1 (0) 0 (0) 0 (0)
PR .002
Positive 1,400 (40) 1,312 (41) 88 (29) 36 (29)
Negative 2,096 (60) 1,883 (59) 213 (71) 90 (71)
Missing/unknown 9 (0) 9 (0) 0 (0) 0 (0)
HER2-positive 3,505 (100) 3,204 (100) 301 (100) 126 (100) N/A§
Mean no. of nodes involved (range) 4.3 (0-41) 4.3 (0-41) 4.9 (0-39) 5.2 (0-39) .053
Tumor size, cm .621
, 2 1,143 (33) 1,041 (32) 102 (34) 45 (36)
$ 2 2,362 (67) 2,163 (68) 199 (66) 82 (64)
CALGB 974135 1,985 1,825 160 52
ER .127
Positive 1,283 (65) 1,026 (56) 114 (71) 37
Negative 668 (34) 757 (41) 46 (29) 15
Missing/unknown 34 (2) 34 (2) 0 (0) 0
PR .818
Positive 1,116 (56) 1,026 (56) 90 (56) 29
Negative 826 (42) 757 (41) 69 (43) 23
Missing/unknown 43 (2) 42 (2) 1 (1) 0 (0)
HER2 Not reliably collected
Positive
Negative
Missing/unknown
Mean no. of nodes involved (range) 4.3 (0-34) 4.1 (0-30) 6.7 (1-34) 6.8 (1-26) , .001
Tumor size, cm .968
, 2 633 (33) 581 (33) 52 (33) 16 (31)
$ 2 1,311 (67) 1,204 (67) 107 (67) 36 (69)
(continued on following page)
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years versus those age , 65 years (overall P , .0001), and early
protocol treatment cessation was more frequent in those age $ 65
years (50%) versus , 65 years (35.9%) across trials. For those
treated in adjuvant trials (Table 4), small differences by age were
seen in the percentage of women who went off protocol treatment
because they completed therapy, with 80.1% of women age , 65
years completing therapy as planned versus 77.4% of women age
$ 65 years (overall P , .0001). For neoadjuvant trials, compar-
isons were limited because 65% of patients did not have clearly
documented reasons for stopping study therapy. Overall, deaths
during a study were uncommon (1% of women age $ 65 years v
0.2% for those age , 65 years). Cessation of therapy because of
adverse events occurred more frequently for those age $ 65 years
compared with those, 65 years (7.9% v 6.4% overall; P, .0001),
though differences were small.
DISCUSSION
The US population is aging and the number of older patients with
breast cancer is expected to rise significantly in the coming de-
cades.49-53 Currently, the median age at diagnosis is 62 years and
approximately 42% of all new breast cancer cases annually are
diagnosed in women age $ 65 years.1 On average, an 80-year-old
woman currently living in the United States will live another
9 years54 and will benefit from optimized systemic therapy for her
breast cancer. Furthermore, nearly 10% of older patients present
with stage III-IV disease,55 and even more have node-positive/
earlier-stage disease with a high probability of recurrence, where
chemotherapy can provide benefit.56-58 Improving the availability
of prospective evidence for this growing number of patients is
crucial to inform decision-making and to optimally serve patients’
medical, emotional, and functional needs.30
In this analysis of Alliance systemic therapy studies during
1985-2012, we observed small increases in accrual of older patients
to adjuvant trials but a significant decrease in accrual to trials in the
neoadjuvant and metastatic disease settings. In general, with the
exception of selected trials dedicated to older patients, the pro-
portion of patients enrolling to clinical trials who were age $ 65
years and, in particular, $ 70 years remained low throughout the
study period, with less than 20% of participants age$ 65 years and
less than 10% of participants age$ 70 years. The absolute numbers
of older patients enrolled over time also remained low, though
some years saw higher accrual than others.
Of note, despite a trend for decreased accrual for metastatic
and neoadjuvant trials for older patients, overall, numerically
higher proportions of older patients enrolled in these trials
compared with adjuvant studies, with approximately 24% of
participants aged $ 65 years in both metastatic and neoadjuvant
studies (v 15% on adjuvant trials). The reasons for this finding are
not clear from the data available but may be related to a lower
threshold for treatment in the neoadjuvant/metastatic settings
Table 2. Disease Characteristics by Adjuvant Trial for Older Versus Younger Women* (continued)
Variables by Protocol Total* Age , 65 Years Age $ 65 Years Age $ 70 Years†
P‡ (age , 65
years v $ 65 years)
CALGB 934436 3,165 2,983 182 55
ER .367
Positive 1,871 (59) 1,757 (59) 114 (63) 32
Negative 1,276 (40) 1,208 (40) 68 (37) 23
Missing/unknown 18 (0) 18 (1) 0 (0) 0 (0)
PR .294
Positive 1,771 (56) 1,675 (56) 96 (53) 27
Negative 1,364 (43) 1,278 (43) 86 (47) 28
Missing/unknown 30 (1) 30 (1) 0 (0) 0 (0)
HER2 Not collected
Positive
Negative
Missing/unknown
Mean no. of nodes involved (range) 5.0 (0-41) 4.9 (0-41) 7.4 (1-36) 7.3 (1-22) , .001
Tumor size, cm .127
, 2 821 (26) 765 (26) 56 (31) 18 (33)
$ 2 2,325 (74) 2,200 (74) 125 (69) 37 (67)
CALGB 854138 1,558 1,411 147 47
ER/PR/HER2 Not collected
Missing
Mean no. of nodes involved (range) 4.6 (1-54) 4.4 (1-38) 6.1 (1-54) 6.6 (1-26) .039
Tumor size, cm .454
, 2 367 (24) 329 (23) 38 (26) 7 (16)
$ 2 1,182 (76) 1,075 (77) 107 (74) 38 (84)
NOTE. Data are given as no. (%) unless otherwise indicated. Dashes indicate no data available.
Abbreviations: CALGB, Cancer and Leukemia Group B; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; N/A, not applicable; NCCTG, North
Central Cancer Treatment Group; PR, progesterone receptor.
*Detailed tumor characteristics for NCCTG 89-30-52 were not available; some sample sizes are smaller than the overall protocol sample because of missing data on
some patients. Comparisons were made among those with known tumor characteristics listed.
†P value not shown for age # 70 years v $ 70 years.
‡Values are for x2 testing for ER/PR/HER2; t tests for tumor size and number of nodes.
§All patients had HER2-positive disease.
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because of symptomatic or higher burden of disease. Furthermore,
all the patients with metastatic disease in the trials included in this
analysis received single-agent chemotherapy, which may be more
appealing for providers and older patients than doublet treatment.
Although there were some differences noted by age in PS for trial
participants, essentially all patients across studies had ECOG PS of
0-1 and met trial eligibility criteria. It is possible that some older
patients who would have otherwise participated in protocols were
disproportionately not eligible because of poor PS, but we do not
have information on patients not enrolled in studies. However,
given that most older patients with cancer have life expectancies
of . 16 years at age 70,54 and that approximately half of older
patients with breast cancer having three or fewer comorbid
conditions,4 it is unlikely that the majority of older patients not
enrolled in trials were truly ineligible.
Not surprisingly, trials administering endocrine therapies also
enrolled higher proportions of older participants, though results
for accrual of older patients were similar even after excluding these
trials. In contrast, in the adjuvant setting, there may be a higher
threshold to treat older patients with chemotherapy in general,
thus leading to fewer older patients enrolled in adjuvant studies.
Consistent with this, we observed more nodal involvement and
more hormone receptor-negative cancers for older (v younger)
women enrolled in adjuvant studies. Although it is often appro-
priate to withhold adjuvant systemic therapy in older patients with
significant comorbidity and/or low-to-intermediate risk tumors,
there are likely many cases in which older women are being
undertreated,56,57,9-64 possibly reflected by their disproportionately
low enrollment in adjuvant trials. For example, in CALGB 9344, an
adjuvant trial for women with node-positive cancers, only 6% of
trial participants were age$ 65 years and 2% were age$ 70 years.
On average, older women on this trial hadmore than seven positive
lymph nodes compared with an average of more than five nodes for
patients age , 65 years, suggesting a higher threshold to treat
despite similar mortality benefits from adjuvant chemotherapy for
older and younger women.55,57,58 However, we do not have in-
formation on whether older women received treatment off-study.
Reassuringly, we observed small differences in the proportion of
patients who stopped therapy for adverse events by age, and # 10%
of all patients stopped therapy for this reason, regardless of age.
Consistent with this, Muss et al24 reported that 92% of patients age
$ 65 years receiving anthracycline-based therapy on CALGB 49907
completed treatment. Deaths while participating in a study in our
analysis were more common for older patients overall (1% for age
$ 65 years v 0.2% for age , 65 years), but nearly half of deaths in
older patients occurred in the metastatic setting and were likely re-
lated to disease progression. Less than 1%of older patients on adjuvant
trials had death as the documented reason for therapy cessation.
Our results suggest that current strategies to increase enrollment
of older adults to Alliance trials have had limited effectiveness. Al-
though chemotherapy-based clinical trials targeting older women,
such as CALGB 49907 and the local therapy trial CALGB 9343
(tamoxifen with or without radiation therapy for women undergoing
breast conservation) have demonstrated the ability to accrue patients
to large-scale, practice-changing trials on a national level, protocols
dedicated to older patients remain few. Consequently, there has been
new momentum to reassess how we approach accrual challenges
across the cancer spectrum. Recently proposed, overarching strategies
to improve prospective evidence have outlined strong recommen-
dations for the following: (1) leverage trial designs by including
Table 3. Eastern Cooperative Oncology Group Performance Status for Patients in Included Studies, by Age and Trial
Study PS
Age Group Age Group
, 65 Years $ 65 Years
P*
, 70 Years $ 70 Years
P*n % n % n % n %
40101 0 3,047 89.5 394 84.2 .0006 3,296 89.2 145 81.9 .003
1 356 10.5 74 15.8 398 10.8 32 18.1
40302 0 154 73.0 44 52.4 .003 177 71.4 21 44.7 .001
1 54 25.6 38 45.2 68 27.4 24 51.1
2 3 1.4 2 2.4 3 1.2 2 4.3
40502 0 400 63.2 100 60.2 .485 448 62.4 52 64.2 .751
1 233 36.8 66 39.8 270 37.6 29 35.8
40503 0 208 70.3 56 57.1 .017 233 68.3 31 58.5 .157
1 88 29.7 42 42.9 108 31.7 22 41.5
40601 0 262 93.6 21 84.0 .076 274 92.9 9 90.0 .729
1 18 6.4 4 16.0 21 7.1 1 10.0
40603 0 376 90.8 32 80.0 .030 401 90.3 7 70.0 .035
1 38 9.2 8 20.0 43 9.7 3 30.0
49907 0 N/A 457 72.2 N/A 175 80.3 282 68.0 .004
1 161 25.4 39 17.9 122 29.4
2 15 2.4 4 1.8 11 2.7
9840 0 153 67.4 39 60.9 .602 169 66.8 23 60.5 .852
1 67 29.5 24 37.5 77 30.4 14 36.8
2 6 2.6 1 1.6 6 2.4 1 2.6
3 1 0.4 1 0.4
NOTE. Eastern Cooperative Oncology Group performance status (ECOG PS) for the protocols where this information available. ECOG PS 0 = full active, able to carry on
all predisease performance without restriction; ECOG PS 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary
nature; ECOG PS 2 = ambulatory and capable of all self-care but unable to carry out any work activities.48 Up and about more than 50% of waking hours.
Abbreviation: N/A, not applicable.
*By study, using x2 testing.
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specific analyses of outcomes for older patients and (2) improve the
research environment for enrollment (eg, nationally based incentives
for enrolling older patients, improving the information collected for
older patients).23,30
Additional ways to incorporate older patients22 could include
strategies that either mandate enrollment of a prespecified pro-
portion or number of older patients in National Institutes of
Health-supported studies or a dedicated “expansion cohort” of
older patients where toxicity, functional decline, and outcomes can
be closely monitored. An alternative strategy could require that all
new National Clinical Trials Network (NCTN) protocols undergo
review to ensure specific considerations and outcomes are included
for older adults. Third, ensuring that clinical trials are extended
to community sites rather than academic institutions will likely
improve the appeal of clinical trials for older patients. With any of
these approaches, we may not need to rely on dedicated clinical
trials for older patients to gain prospective data. This would also
reduce the need to pool clinical trial data from heterogeneous
groups of patients to answer questions about the experiences,
toxicities, and disease outcomes for older patients.58,65
We recognize several important limitations. We did not have
information on the numbers of women approached or not
approached, the characteristics of providers and practices, trial
burden or requirements, or why patients did not enroll. Second,
because the focus of our analysis was limited to Alliance systemic
therapy trials, our results cannot be extrapolated across all breast
cancer studies. Furthermore, we do not have information on how
our results compare with those from other cooperative group
settings or clinical trials in general, because of the lack of previously
published data. Third, we did not have complete information on
PS, reasons for therapy cessation, and tumor characteristics for
some trials. Also, some tumor characteristics may be misclassified
in some cases because they relied on previously collected data.
Finally, interpretation of results from neoadjuvant trials may be
limited by the smaller number of patients enrolled overall and the
fact that two of these trials (CALGB 40603 and 40601) targeted
patients with tumor subtypes that occur less frequently in older
(v younger) patients.66
Despite these limitations, we were able to examine breast cancer
systemic treatment trials over time on a national scale, further
highlighting previous findings across all cancers22,23 and identifying
areas in urgent need of improvement within breast cancer NCTN
trials. Our findings serve as an urgent call to action: Novel strategies
for accrual of older patients to clinical trials are critical to mean-
ingfully change the evidence-base for this growing group. The
NCTN has the power to effect meaningful change on a national
level with regard to the care of older patients with cancer and should
seize this opportunity to forge a new path in clinical trial strategy.
Table 4. Reasons for Study Therapy Cessation by Age for All Studies and by Trial Type
Reason for Going Off Study
All Ages,
Total No. (%) Age , 65 Years, No. (%)
Age $ 65 Years,
No. (%) P
All studies combined 13,763 11,336 2,427 , .0011
Adverse event 911 (6.6) 720 (6.4) 191 (7.9)
Completed per protocol 8,481 (61.6) 7,267 (64.1) 1,214 (50.0)
Death 43 (0.3) 19 (0.2) 24 (1.0)
Disease progressed/new primary 1,274 (9.3) 994 (8.8) 280 (11.5)
Never started 245 (1.8) 208 (1.8) 37 (1.5)
Other disease; other therapy; other/missing 2,180 (15.9) 1,623 (14.3) 554 (22.9)
Refused further treatment 616 (4.5) 494 (4.4) 122 (5.0)
Adjuvant studies (n = 10,014)* , .001
Adverse event 702 (7.0) 568 (6.7) 134 (8.8)
Completed per protocol 7,981 (79.7) 6,806 (80.1) 1,175 (77.4)
Death 21 (0.2) 8 (0.1) 13 (0.9)
Disease progressed/new primary 86 (0.9) 75 (0.9) 11 (0.7)
Never started 183 (1.8) 156 (1.8) 27 (1.8)
Other disease; other therapy; other/missing 636 (6.4) 552 (6.5) 84 (5.5)
Refused further treatment 405 (4.0) 330 (3.9) 75 (4.9)
Neoadjuvant studies (n = 1,669) .028
Adverse event 46 (2.8) 39 (3.1) 7 (1.7)
Completed per protocol 493 (29.5) 456 (36.1) 37 (9.1)
Disease progressed/new primary 12 (0.7) 11 (0.9) 1 (0.2)
Never started 13 (0.8) 11 (0.9) 2 (0.5)
Other disease; other therapy; other/missing 1,083 (64.9) 725 (57.4) 358 (88.0)
Refused further treatment 22 (1.3) 20 (1.6) 2 (0.5)
Metastatic studies† (n = 2,074) , .001
Adverse event 163 (7.9) 113 (7.2) 50 (10.0)
Completed per protocol 8 (0.4) 6 (0.4) 2 (0.4)
Death 22 (1.1) 11 (0.7) 11 (2.2)
Disease progressed/new primary 1,181 (56.9) 912 (57.9) 269 (54.0)
Never started 50 (2.4) 41 (2.6) 9 (1.8)
Other disease; other therapy; other/missing 461 (22.2) 349 (22.1) 112 (22.5)
Refused further treatment 189 (9.1) 144 (9.1) 45 (9.0)
*Excluding North Central Cancer Treatment Group (NCCTG) 89-30-52, Cancer and Leukemia Group B (CALGB) 8541, CALGB 9344, and CALGB 9342, for which this
information was not available.
†Excluding CALGB 9342, for which this information was not available.
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Fig A1. Absolute numbers of patients enrolled onto clinical trials for all patients age $ 65 years and age $ 70 years (A), by trial type for age $ 65 years and $ 70 years
(B, C), and after exclusion of Cancer and Leukemia Group B (CALGB) 49907, North Central Cancer Treatment Group (NCCTG) 89-30-52, and American College of Surgeons
Oncology Group (ACOSOG) Z1031 (D).
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